相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Fracture Risk and Management of Discontinuation of Denosumab Therapy: A Systematic Review and Position Statement by ECTS
Elena Tsourdi et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2021)
Risk factors for bisphosphonate-associated osteonecrosis of the jaw in the prospective randomized trial of adjuvant bisphosphonates for early-stage breast cancer (SWOG 0307)
Darya A. Kizub et al.
SUPPORTIVE CARE IN CANCER (2021)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Updated guidance on the management of cancer treatment-induced bone loss (CTIBL) in pre- and postmenopausal women with early-stage breast cancer
Komal Waqas et al.
JOURNAL OF BONE ONCOLOGY (2021)
Efficacy of zoledronic acid for prevention of bone loss in early-stage breast cancer patients receiving adjuvant therapy: A meta-analysis of 13 randomized controlled trials
Mei Mei et al.
CURRENT PROBLEMS IN CANCER (2020)
Increased Fracture Risk in Women Treated With Aromatase Inhibitors Versus Tamoxifen: Beneficial Effect of Bisphosphonates
Marta Pineda-Moncusi et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2020)
Bone modifying agents for bone loss in patients with aromatase inhibitor as adjuvant treatment for breast cancer; insights from a network meta-analysis
Hirotaka Miyashita et al.
BREAST CANCER RESEARCH AND TREATMENT (2020)
Phase 2 placebo-controlled, single-blind trial to evaluate the impact of oral ibandronate on bone mineral density in osteopenic breast cancer patients receiving adjuvant aromatase inhibitors: 5-year results of the single-centre BONADIUV trial
Lorenzo Livi et al.
EUROPEAN JOURNAL OF CANCER (2019)
French recommendations on strategies for preventing and treating osteoporosis induced by adjuvant breast cancer therapies
Beatrice Bouvard et al.
JOINT BONE SPINE (2019)
Management of Osteoporosis in Survivors of Adult Cancers With Nonmetastatic Disease: ASCO Clinical Practice Guideline
Charles L. Shapiro et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension
Steven R. Cummings et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2018)
Assessment and management of bone health in women with oestrogen receptor-positive breast cancer receiving endocrine therapy: Position statement of the Endocrine Society of Australia, the Australian and New Zealand Bone & Mineral Society, the Australasian Menopause Society and the Clinical Oncology Society of Australia
Mathis Grossmann et al.
CLINICAL ENDOCRINOLOGY (2018)
Fracture Prevention with Zoledronate in Older Women with Osteopenia
Ian R. Reid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Comparative Efficacy and Safety of Adjuvant Letrozole Versus Anastrozole in Postmenopausal Patients With Hormone Receptor-Positive, Node-Positive Early Breast Cancer: Final Results of the Randomized Phase III Femara Versus Anastrozole Clinical Evaluation (FACE) Trial
Ian Smith et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Comparing the incidence of bone tumors in rats chronically exposed to the selective PTH type 1 receptor agonist abaloparatide or PTH(1-34)
Jacquelin Jolette et al.
REGULATORY TOXICOLOGY AND PHARMACOLOGY (2017)
Improvement of Bone Physiology and Life Quality Due to Association of Risedronate and Anastrozole
Vincenzo Monda et al.
FRONTIERS IN PHARMACOLOGY (2017)
Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO, IMS, and SIOG
Peyman Hadji et al.
JOURNAL OF BONE ONCOLOGY (2017)
Clinical effectiveness of bisphosphonates for the prevention of fragility fractures: A systematic review and network meta-analysis
Jean Sanderson et al.
BONE (2016)
Preventive effect of zoledronic acid on aromatase inhibitor-associated bone loss for postmenopausal breast cancer patients receiving adjuvant letrozole
Shengliang Sun et al.
ONCOTARGETS AND THERAPY (2016)
5-year follow-up of a randomized controlled trial of immediate versus delayed zoledronic acid for the prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen: N03CC (Alliance) trial
Nina D. Wagner-Johnston et al.
CANCER (2015)
Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial
Michael Gnant et al.
LANCET (2015)
Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials
R. Coleman et al.
LANCET (2015)
Prevention of bone loss with risedronate in breast cancer survivors: a randomized, controlled clinical trial
S. L. Greenspan et al.
OSTEOPOROSIS INTERNATIONAL (2015)
Bisphosphonates May Protect against Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Aromatase Inhibitor Therapy: Results from a Meta-analysis
Guoqiang Su et al.
ARCHIVES OF MEDICAL RESEARCH (2014)
Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B): a companion analysis of a randomised controlled trial
Paul E. Goss et al.
LANCET ONCOLOGY (2014)
The Efficacy of Bisphosphonates in Preventing Aromatase Inhibitor Induced Bone Loss for Postmenopausal Women with Early Breast Cancer: A Systematic Review and Meta-Analysis
Pooleriveetil Padikkal Anagha et al.
JOURNAL OF ONCOLOGY (2014)
Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results
R. Coleman et al.
ANNALS OF ONCOLOGY (2013)
Efficacy of zoledronic acid in postmenopausal Japanese women with early breast cancer receiving adjuvant letrozole: 12-month results
Shunji Takahashi et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Immediate Administration of Zoledronic Acid Reduces Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women With Early Breast Cancer: 12-Month Analysis of the E-ZO-FAST Trial
Antonio Llombart et al.
CLINICAL BREAST CANCER (2012)
Osteosarcoma in Sprague-Dawley rats after long-term treatment with teriparatide (human parathyroid hormone (1-34))
Atsushi Watanabe et al.
JOURNAL OF TOXICOLOGICAL SCIENCES (2012)
Effects of zoledronic acid on bone mineral density during aromatase inhibitor treatment of Korean postmenopausal breast cancer patients
Seung Ah Lee et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
Aromatase inhibitor-associated bone and musculoskeletal effects: new evidence defining etiology and strategies for management
Stephanie Gaillard et al.
BREAST CANCER RESEARCH (2011)
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Julian P. T. Higgins et al.
BMJ-BRITISH MEDICAL JOURNAL (2011)
Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study
H. Eidtmann et al.
ANNALS OF ONCOLOGY (2010)
The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer
R. E. Coleman et al.
BRITISH JOURNAL OF CANCER (2010)
Lack of evidence for fracture prevention in early breast cancer bisphosphonate trials: A meta-analysis
Antonis Valachis et al.
GYNECOLOGIC ONCOLOGY (2010)
Characterization of and Risk Factors for the Acute-Phase Response after Zoledronic Acid
I. R. Reid et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
Prevention of Aromatase Inhibitor-Induced Bone Loss Using Risedronate: The SABRE Trial
Catherine Van Poznak et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial
Jack Cuzick et al.
LANCET ONCOLOGY (2010)
Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial
Christos Markopoulos et al.
BREAST CANCER RESEARCH (2010)
Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial
M. Rabaglio et al.
ANNALS OF ONCOLOGY (2009)
Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC
Stephanie L. Hines et al.
BREAST CANCER RESEARCH AND TREATMENT (2009)
Zoledronic Acid Effectively Prevents Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole: Z-FAST Study 36-Month Follow-up Results
Adam M. Brufsky et al.
CLINICAL BREAST CANCER (2009)
Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis
Peyman Hadji
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2009)
Prevention of Anastrozole-Induced Bone Loss with Monthly Oral Ibandronate during Adjuvant Aromatase Inhibitor Therapy for Breast Cancer
James E. Lester et al.
CLINICAL CANCER RESEARCH (2008)
Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230
Richard Eastell et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate: Review of statistical analysis - Response
Richard Eastell et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2007)
Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer
Adam Brufsky et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study
Robert E. Coleman et al.
LANCET ONCOLOGY (2007)
Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: The Fracture Intervention Trial
DC Bauer et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2004)
Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate
R Eastell et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2003)
Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer
CL Shapiro et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib
T Mashiba et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2000)
分享论文
